 BOSTON, April 28, 2022 GLOBE NEWSWIRE -- Ikena Oncology, Inc. Nasdaq: IKNA, Ikena, a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical Oncology ASCO 2022 Annual Meeting. The presentations will include overviews of the clinical trials for Ikenas novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor AHR antagonist, IK-175. Both posters will be presented by the trials investigators. 